Q-omics provides the consensus-scored UBOX5 profile across patient tissues and cancer cell-line models. UBOX5 expression is associated with patient survival in 24 of 34 cancer types, with the highest sampling consensus in LIHC. Among the 18 cancer types available for tumor–normal comparison, UBOX5 is differentially expressed in 12, with the highest sampling consensus in LIHC. Additionally, UBOX5 RNA expression shows 17,761 significant gene co-expression associations, with the highest sampling consensus in TGCT. Together, these results highlight LIHC, and TGCT as cancer lineages where UBOX5 shows reproducible signals across survival, tumor–normal expression, and patient cross-omics analyses.
Every result is evaluated using two consensus scores. Sampling consensus measures how consistently a finding is reproduced within a cancer lineage across different conditions. Lineage consensus measures how broadly the result is shared across cancer types, distinguishing pan-cancer signals from lineage-specific patterns.
Premium analyses for UBOX5 — synthetic lethality, tumor antigen, and pembrolizumab response.
This table summarizes UBOX5 survival associations across molecular data types. UBOX5 RNA expression shows survival associations in the most cancer types (24), followed by mutation status (5) and mass-spec protein abundance (5). The rightmost column indicates the cancer type with the highest sampling consensus for each molecular layer.
This table ranks reproducible UBOX5 RNA expression–survival associations across cancer types. High UBOX5 expression shows unfavorable associations in LIHC and KICH, but favorable associations in PAAD, KIRC, UCEC and THYM. The LIHC Kaplan–Meier curve shows clear separation, with the high-expression group declining faster, consistent with the unfavorable association (log-rank p < 0.001). Together, the overview and detailed table identify LIHC as the clearest survival context for UBOX5 RNA expression.
This table summarizes UBOX5 tumor–normal expression differences by data type. RNA shows broader differences across cancer types, with a lineage consensus of 12, while mass-spec protein shows differences in 5. The strongest signals are observed in LIHC for RNA and HNSC for protein.
This table ranks reproducible tumor–normal expression differences for UBOX5. A negative fold-change indicates higher expression in normal tissue than in tumor tissue. UBOX5 shows lower tumor expression in LUAD, BLCA and UCEC and higher tumor expression in LIHC, HNSC and CHOL. The LIHC box plot shows higher UBOX5 RNA expression in tumor versus normal tissue (log2 FC = +1.060, t-test p < 0.001).
This table shows molecular features associated with UBOX5 in patient tissues and cancer cell lines. In patient samples, UBOX5 shows the broadest associations at the RNA and protein expression levels, with TGCT recurring as the lineage with the largest associated feature set. In cancer cell lines, UBOX5 RNA and mutation anchors are most strongly linked to RNA-expression features, especially in BLOOD_Myeloma, while CRISPR and shRNA rows add functional-dependency signals in SOFT_TISSUE and BLOOD_Leukemia.
